ArticleJournal of cardiovascular translational research2010
c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells.
Article in Journal of cardiovascular translational research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Pooled it
- L-Cells · 2021Article
- Pre-clinical Investigation of Rett Syndrome Using Human Stem Cell-Based Disease Models.Frontiers in neuroscience · 2021Review
- Article
- A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair.European heart journal · 2020Article
- HiPS-Cardiac Trilineage Cell Generation and Transplantation: a Novel Therapy for Myocardial Infarction.Journal of cardiovascular translational research · 2020Review
- Emergence of Three Dimensional Printed Cardiac Tissue: Opportunities and Challenges in Cardiovascular Diseases.Current cardiology reviews · 2019Review
- The march of pluripotent stem cells in cardiovascular regenerative medicine.Stem cell research & therapy · 2018Review
- Systems-based technologies in profiling the stem cell molecular framework for cardioregenerative medicine.Stem cell reviews and reports · 2015Review
- Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.Regenerative medicine · 2015Review
- iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes.Circulation. Cardiovascular genetics · 2014Article
- Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy.Stem cells and development · 2014Article
- Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity.Stem cells (Dayton, Ohio) · 2014Article
- The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine.Stem cell reviews and reports · 2014Article
- ΔNp63 regulates select routes of reprogramming via multiple mechanisms.Cell death and differentiation · 2013Article
- Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines.Circulation. Cardiovascular genetics · 2013Article
- New and TALENted genome engineering toolbox.Circulation research · 2013Review
- Low oxygen tension enhances proliferation and maintains stemness of adipose tissue-derived stromal cells.BioResearch open access · 2013Article
- The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Cell cycle (Georgetown, Tex.) · 2013Article
- Nuclear reprogramming with c-Myc potentiates glycolytic capacity of derived induced pluripotent stem cells.Journal of cardiovascular translational research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Induced pluripotent stem cell (iPS) technology has launched a new platform in regenerative medicine aimed at deriving unlimited replacement tissue from autologous sources through somatic cell reprogramming using stemness factor sets. In this way, authentic cardiomyocytes have been obtained from iPS and recently demonstrated in proof-of-principle studies to repair infarcted heart. Optimizing the cardiogenic potential of iPS progeny would ensure a maximized yield of bioengineered cardiac tissue. Here, we reprogrammed fibroblasts in the presence or absence of c-MYC to determine if the acquired cardiogenicity is sensitive to the method of nuclear reprogramming. Using lentiviral constructs that expressed stemness factors SOX2, OCT4, and KLF4 with or without c-MYC, iPS clones generated through fibroblast reprogramming demonstrated indistinguishable characteristics for 5 days of differentiation with similar cell morphology, growth rates, and chimeric embryo integration. However, 4-factor c-MYC dependent nuclear reprogramming produced iPS progeny that consistently prolonged the expression of pluripotent Oct-4 and Fgf4 genes and repressed cardiac differentiation. In contrast, 3-factor c-MYC-less iPS clones efficiently up-regulated pre-cardiac (CXCR4, Flk-1, and Mesp1/2) and cardiac (Nkx2.5, Mef2c, and Myocardin) gene expression patterns. In fact, 3-factor iPS progeny demonstrated early and robust cardiogenesis during in vitro differentiation with consistent beating activity, sarcomere maturation, and rhythmical intracellular calcium dynamics. Thus, nuclear reprogramming independent of c-MYC enhances production of pluripotent stem cells with innate cardiogenic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.